Thirty years ago this year, the introduction of a new treatment approach changed the course of the HIV epidemic. For the first time, combination drug therapy could suppress the virus instead of merely slowing it, transforming HIV from what was widely considered a death sentence into a manageable chronic disease. The breakthrough, known as Highly Active Antiretroviral Therapy (HAART), gave people living with HIV a future they had never been promised.
Before HAART, doctors fought HIV with one drug at a time. The first medication, AZT, was approved in 1987 and offered hope but only temporarily slowed the virus while causing severe side effects. HIV often adapted and became resistant, leaving many patients with few options. That began to change in late 1995 with the approval of the first protease inhibitor. These drugs blocked HIV from making mature copies of itself, allowing doctors to combine medications that attacked the virus from multiple angles. The breakthrough reached a global audience in July 1996 at the International AIDS Conference in Vancouver, where researchers unveiled dramatic results: the new combination therapies could suppress HIV to previously unimaginable levels. Patients once expected to die were regaining weight, leaving hospitals and returning to work.
For long-term survivors, the arrival of HAART did not erase the trauma of the preceding years overnight. The first generation of lifesaving medications often came with grueling side effects, including nausea and chronic diarrhea. Pills had to be taken at precise times, sometimes on an empty stomach, sometimes with food. Many survivors recall sleeping in bathrooms to stay close to toilets. Yet the results became impossible to ignore. As one survivor wrote in his award-winning blog, people literally got out of bed. It became known as the Lazarus Syndrome. Two years later, in August 1998, the Bay Area Reporter published a story titled "No Obits", marking the first week since the epidemic began that the newspaper had not received a single obituary for someone who had died of the virus.
Today, HIV treatment bears little resemblance to the complicated regimens that defined the early years of HAART. Many people now take a single pill each day, while others have the option of long-acting injectable medications administered every one to two months. The advances that followed HAART also led to PrEP, a medication that prevents HIV infection and has become one of the most powerful tools in reducing new transmissions. As long-term survivors mark this anniversary, they are navigating a new set of challenges that come with aging with the virus. But the central achievement remains: three decades after HAART, millions of people living with HIV are not just surviving but thriving, with the promise of continued progress in treatment and prevention on the horizon.